Multi-functional organic gelator derived from phenyllactic acid for phenol removal and oil recovery.

Supramolecular gels, a fascinating class of soft materials, are of great interest for their wide applications. In this work, a series of organic gelators derived from phenyllactic acid were prepared, and their gelation properties were further investigated. It was found that the gelator 1e bearing a hydrazine moiety could congeal 17 kinds of common organic liquids (polar and non-polar) efficiently. Meanwhile, the morphological structures and dominant factors of the gel were examined by scanning electron microscope (SEM), transmission electron microscope (TEM), Fourier transform infrared spectroscopy (FT-IR), concentration and temperature-dependent 1H NMR. Crucially, the gelator displayed outstanding performances in toxic phenol removal and spilled oil and petroleum products recovery. Moreover, it also displayed a satisfactory recyclability, which will greatly promote its application in practice. These impressive results will provide a novel avenue for the water treatment and the development of functional supramolecular gel materials.

Camptothecin-Polysaccharide Co-assembly and Its Controlled Release.

ß-Cyclodextrin modified camptothecin (CPT-CD) was synthesized through esterification reaction and "click chemistry" to greatly improve the solubility of CPT in aqueous solution, and then, a supramolecular nanoparticle was constructed by strong noncovalent interaction between ß-cyclodextrin and adamantane and amphiphilic interaction by simply mixing CPT-CD and adamantane modified hyaluronic acid (HA-ADA) together. The obtained nanoparticle had a hydrophilic HA shell, which could target and recognize HA receptors overexpressed on the surface of cancer cells, and a hydrophobic CPT core, which could protect CPT from hydrolyzation. The results of cytotoxicity experiments showed that the nanoparticle we have designed in this work exhibited similar anticancer activities to, but with much lower side effects than, the commercial chemotherapeutic drug CPT in vitro. We believe that this work might provide a strategy for improving the treatment performance of CPT in laboratory and clinical settings.